Login / Signup

Meeting Summary of The NYO3 5th NO-Age/AD Meeting and the 1st Norway-UK Joint Meeting on Aging and Dementia: Recent Progress on the Mechanisms and Interventional Strategies.

He-Ling WangRichard SiowTomas Schmauck-MedinaJianying ZhangPer Morten SandsetClare FilshieØystein LundLinda PartridgeLinda Hildegard BergersenLene Juel RasmussenKonstantinos PalikarasIoannis SotiropoulosJon Storm-MathisenDavid C RubinszteinMaria Grazia SpillantiniChris I De ZeeuwLeiv Otto WatneMartin VyhnalekKaterina VeverovaKristina Xiao LiangNektarios TavernarakisVilhelm A BohrKoutaro YokoteJanna SaarelaHilde Loge NilsenEfstathios S GonosMorten Scheibye-KnudsenGuobing ChenHisaya KatoGeir SelbækTormod FladbyPer NilssonAnne SimonsenDag AarslandSofie LautrupOle Petter OttersenLynne S CoxEvandro F Fang
Published in: The journals of gerontology. Series A, Biological sciences and medical sciences (2024)
Unhealthy aging poses a global challenge with profound healthcare and socioeconomic implications. Slowing down the aging process offers a promising approach to reduce the burden of a number of age-related diseases, such as dementia, and promoting healthy longevity in the old population. In response to the challenge of the aging population and with a view to the future, Norway and the United Kingdom are fostering collaborations, supported by a "Money Follows Cooperation agreement" between the 2 nations. The inaugural Norway-UK joint meeting on aging and dementia gathered leading experts on aging and dementia from the 2 nations to share their latest discoveries in related fields. Since aging is an international challenge, and to foster collaborations, we also invited leading scholars from 11 additional countries to join this event. This report provides a summary of the conference, highlighting recent progress on molecular aging mechanisms, genetic risk factors, DNA damage and repair, mitophagy, autophagy, as well as progress on a series of clinical trials (eg, using NAD+ precursors). The meeting facilitated dialogue among policymakers, administrative leaders, researchers, and clinical experts, aiming to promote international research collaborations and to translate findings into clinical applications and interventions to advance healthy aging.
Keyphrases
  • mild cognitive impairment
  • healthcare
  • dna damage
  • risk factors
  • clinical trial
  • cognitive impairment
  • oxidative stress
  • randomized controlled trial
  • cross sectional
  • cell death
  • signaling pathway
  • genome wide
  • phase iii